Masatoshi Kudo
Sapporo Medical University(JP)Sapporo University(JP)The Football Association(GB)University of the Ryukyus(JP)Sapporo Higashi Tokushukai Hospital(JP)Kindai University Hospital(JP)Kindai University Sakai Hospital(JP)Japan Society of Ultrasonics in Medicine(JP)CHA University Bundang Medical Center(KR)Shizuoka Red Cross Hospital(JP)University of the Ryukyus University Hospital(JP)Kindai University(JP)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Pancreatic and Hepatic Oncology Research, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma(2020)6,907 cited
- → A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.(2017)5,940 cited
- → Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial(2018)5,304 cited
- → Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial(2017)4,261 cited
- → Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial(2016)3,612 cited
- → Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial